The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRASG12D-driven non-small cell lung cancer
W. J. McDaid, L. Wilson, H. Adderley, M. J. Baker, J. Searle, L. Ginn, T. Budden, M. Aldea, A. Marinello, J. Aredo, A. Viros, B. Besse, H. A. Wakelee, F. Blackhall, C. R. Lindsay, A. Malliri
This study compares KRASG12C and KRASG12D mutant NSCLC models, finding that KRASG12D relies more on the PI3K-AKT-mTOR pathway, suggesting tailored combination therapies.
bioRxiv · Sep 20, 2023Cancer Biology